Johnson & Johnson said that, as part of its previously announced $55B investment to support U.S. manufacturing, it is announcing two new U.S. manufacturing facilities, including a next generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina. Additionally, construction is progressing on its $2B state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which the company broke ground on last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- J&J reaches pact with U.S. government over access to medicines
- Lexeo Therapeutics announces research collab with Johnson & Johnson
- LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze
- Johnson & Johnson submits Ottava Robotic Surgical System to the FDA
- Apogee Therapeutics Stock (APGE) Plunges despite ‘Positive’ Asthma Drug Trial